Because the Right Start Matters Most

Order a test

About

OncoHost’s first test, PROphet® NSCLC, guides first-line immunotherapy treatment decisions for advanced, unresectable non-small cell lung cancer patients.

Requiring just one pre-treatment blood test, PROphet® scans approximately 7,000 proteins in a patient's plasma and delivers a report that predicts their clinical benefit probability in response to PD-1/PD-L1 inhibitors.

PROphet® NSCLC provides clinicians with actionable clinical insights into optimal first-line therapeutic choices, and a better understanding of their patient's personalized cancer dynamics.

The PROphet® NSCLC test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans.

From plasma proteomics to clinical utility

Clinical Validation

The PROphet® model was developed using patient blood samples and clinical data collected within the framework of an ongoing clinical study conducted by OncoHost (PROPHETIC; NCT04056247). In brief, pre-treatment blood samples were collected from 630 advanced-stage non-small cell lung cancer (NSCLC) patients, out of which 545 were receiving PD-1/PD-L1 inhibitors with or without chemotherapy, and 85 were being treated with chemotherapy.

Patient clinical data were recorded, including demographics, clinical characteristics, and clinical benefit. Blood plasma was profiled by the SomaScan® Discovery Assay v4.1, and the resulting proteomic profiles were analyzed in conjunction with patient clinical data. Specifically, a proprietary prediction algorithm was developed to identify proteomic patterns associated with clinical benefit in response to PD-1/PD-L1 inhibitors.

Learn more
Lab

Unique mathematical model, no overfitting, no false discoveries

Model development is based on blinded validation

1. Identity differentially expressed proteins: Resistance Associated Proteins (RAPs)

2. Each RAP is an alert that can be either:

3. The collection of “on” and “off” RAPs forms an individual resistance map

Patient A

Higher probability
of clinical benefit

Patient B

Lower probability of
clinical benefit

RAPs=Resistance Associated Proteins

*Clinical benefit is defined as progression-free survival at 12 months: PFS<12 months = low clinical benefit & PFS>12 months = high clinical benefit

Actionable clinical insights, optimal choice of therapy, and better understanding of the patient’s personalized cancer dynamics

The PROphet® Report

A decision support tool with a 7–14-day turnaround

The PROphet® report shows a prediction of the patient’s clinical benefit (progression-free survival >12 months) from PD-1/PD-L1 inhibitor immunotherapy-based treatment plans.

Combining these findings with a patient’s PD-L1 level allows for a clear distinction between those who will benefit from immunotherapy alone versus immunotherapy combined with chemotherapy. This may improve the patient’s overall response rate.

PROphet® thereby addresses one of the most common daily dilemmas of the oncologist with an accuracy and level of resolution that simply does not exist today.

POSITIVE or NEGATIVE PROphet® score

A measure of the patient's predicted clinical benefit from PD-1/PD-L1 inhibitors.

Treatment considerations

Options the physician may consider based on the patient's PROphet® score and PD-L1 results combined.

Clinical evidence

The scientific research that is the foundation of the PROphet® test.

Available treatment options

Including approved therapies and clinical trials.
Order a test

Customer Testimonials

To date, we do not have a very effective way of predicting response to therapy for these patients. PROphet®️ is an answer to that dilemma. It️ helps me understand just how much therapy I need in my patients with advanced NSCLC and reassures me in my decision-making.

Dr. Jason Porter

PROphet®️ helps guide my treatment decisions by predicting patient response and better understanding how the treatment will work. The test is easy to obtain and reliable.

Dr. Venkat Pavan Kancharla

PROphet®️ is a new technology that allows us to see who will have significant benefit from IO alone, therefore potentially avoiding the need for chemo and over-treating patients.

Dr. Sam Huang

I had a few patients who had high PD-L1, with no response to single-agent Pembro treatment, and with rapidly progressive disease. PROphet®️ has been very helpful in this setting.

Dr. Geeta Kurra

PROphet®️ in my opinion is not only predictive but also prognostic. What stands out about the test is its strong validation process and being quick and easy to obtain.

Dr. Edgardo Santos

To date, we do not have a very effective way of predicting response to therapy for these patients. PROphet®️ is an answer to that dilemma. It️ helps me understand just how much therapy I need in my patients with advanced NSCLC and reassures me in my decision-making.

Dr. Jason Porter

PROphet®️ helps guide my treatment decisions by predicting patient response and better understanding how the treatment will work. The test is easy to obtain and reliable.

Dr. Venkat Pavan Kancharla

PROphet®️ is a new technology that allows us to see who will have significant benefit from IO alone, therefore potentially avoiding the need for chemo and over-treating patients.

Dr. Sam Huang

I had a few patients who had high PD-L1, with no response to single-agent Pembro treatment, and with rapidly progressive disease. PROphet®️ has been very helpful in this setting.

Dr. Geeta Kurra

PROphet®️ in my opinion is not only predictive but also prognostic. What stands out about the test is its strong validation process and being quick and easy to obtain.

Dr. Edgardo Santos

ISLB Webinar

On March 7, 2023, we partnered with the International Society of Liquid Biopsy (ISLB) to discuss unmet needs in predictive 
immuno-oncology biomarkers.

Agenda

Prof. David Gandara, MD – The Unmet Need for Predictive Biomarkers of Immunotherapy

Dr. Ofer Sharon - PROphet®: A Plasma Proteomic Predictive Biomarker for Immunotherapy

Prof. David Carbone - PROphet®: Validation & Clinical Utility

Our Lab

Our lab uses high-throughput protein analysis technology to quantify the levels of thousands of proteins in a single plasma sample. The proteins include cytokines, chemokines, growth factors, and enzymes associated with therapy resistance and tumor spread.

The lab is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the Commission on Office Laboratory Accreditation (COLA). The PROphet® NSCLC test is intended for clinical purposes.

*CLIA number: 34D2250951

Laboratory Certificates & State Permits

Early Access Program

We are currently enrolling select U.S.-based cancer centers into our Early Access Program.

If you’d like to participate, please fill in the form below and we will be in touch to review the PROphet® NSCLC test ordering process in more detail with you and your staff.

Please fill your first name
Please fill your last name
Please enter a valid email adderss
Please fill your institution name
Submit

Your message has been sent

A relevant contact will be in touch soon

Send again
Oops! Something went wrong while submitting the form.

Resources